Home ›› Cancer Programs ›› Thoracic Research & Publications

2016

  • Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.  Wakelee H, Zvirbule Z, De Braud F, Kingsley CD, Mekhail T, Lowe T, Schütte W, Lena H, Lawler W, Braiteh F, Cosgriff T, Kaen D, Boyer M, Hsu J, Phan S, Novello S. Clin Lung Cancer. 2016 Oct 19. pii: S1525-7304(16)30241-8. doi: 10.1016/j.cllc.2016.09.013. [Epub ahead of print] 
  • P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153: Track: Immunotherapy. Waterhouse D, Horn L, Reynolds C, Spigel D, Chandler J, Mekhail T, Mohamed M, Creelan B, Blankstein KB, Nikolinakos P, Mccleod MJ, Li A, Waxman IM, Aanur N, Agrawal S, Richardet E. J Thorac Oncol. 2016 Oct;11(10S):S236. doi: 10.1016/j.jtho.2016.08.104. No abstract available.
  • Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. J Clin Oncol. 2016 Aug 20;34(24):2858-65. doi: 10.1200/JCO.2015.63.5888. 
  • Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.  Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH; study investigators. Lancet Oncol. 2016 Feb;17(2):234-42. doi: 10.1016/S1470-2045(15)00488-X. 
  • Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/JCO.2015.63.9443.
  • Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI. J Clin Oncol. 2016 Dec;34(34):4079-4085.
  • Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes. Hirsh V, Ko A, Pilot R, Renschler MF, Socinski MA. Clin Lung Cancer. 2016 Sep;17(5):367-374. doi: 10.1016/j.cllc.2016.04.002.
  • Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR. Ann Oncol. 2016 Aug;27(8):1573-9. doi: 10.1093/annonc/mdw214.
  • The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. Reck M, Socinski MA, Luft A, Szczęsna A, Dediu M, Ramlau R, Losonczy G, Molinier O, Schumann C, Gralla RJ, Bonomi P, Brown J, Soldatenkova V, Chouaki N, Obasaju C, Peterson P, Thatcher N. J Thorac Oncol. 2016 Jun;11(6):808-18. doi: 10.1016/j.jtho.2016.03.002.
  • Outcomes in patients with brain metastasis from esophageal carcinoma. Kothari N, Mellon E, Hoffe SE, Frakes J, Shridhar R, Pimiento J, Meredith K, Tran ND, Saeed N, Almhanna K. J Gastrointest Oncol. 2016 Aug;7(4):562-9. doi: 10.21037/jgo.2016.03.12.
  • Small caliber covered self-expanding metal stents in the management of malignant dysphagia. Kucera S, Barthel J, Klapman J, Shridhar R, Hoffe S, Harris C, Almhanna K, Meredith K. J Gastrointest Oncol. 2016 Jun;7(3):411-9. doi: 10.21037/jgo.2015.12.03.
  • Determining the optimal number of lymph nodes harvested during esophagectomy. Almhanna K, Weber J, Shridhar R, Hoffe S, Strosberg J, Meredith K. J Gastrointest Oncol. 2016 Jun;7(3):387-94. doi: 10.21037/jgo.2015.12.02.
  • Effect of body mass index on operative outcome after robotic-assisted Ivor-Lewis esophagectomy: retrospective analysis of 129 cases at a single high-volume tertiary care center. Salem AI, Thau MR, Strom TJ, Abbott AM, Saeed N, Almhanna K, Hoffe SE, Shridhar R, Karl RC, Meredith KL.  Dis Esophagus. 2016 May 4. doi: 10.1111/dote.12484. [Epub ahead of print]
  • Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient's undergoing neoadjuvant chemoradiotherapy. Shridhar R, Abbott AM, Doepker M, Hoffe SE, Almhanna K, Meredith KL. J Gastrointest Oncol. 2016 Apr;7(2):206-12. doi: 10.3978/j.issn.2078-6891.2015.104.
  • AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy. Saeed N, Shridhar R, Hoffe S, Almhanna K, Meredith KL. J Gastrointest Oncol. 2016 Apr;7(2):158-65. doi: 10.3978/j.issn.2078-6891.2015.067. 
Back to Top

2015

  • Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. Ou SI, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. J Clin Oncol. 2015 Nov 23. pii: JCO639443. [Epub ahead of print]
  • Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. Halmos B, Pennell NA, Fu P, Saad S, Gadgeel S, Otterson GA, Mekhail T, Snell M, Kuebler JP, Sharma N, Dowlati A.  Oncologist. 2015 Nov;20(11):1298-303. doi: 10.1634/theoncologist.2015-0136. Epub 2015 Aug 25.
  • The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, Shridhar R, Frakes J, Coppola D, Pimiento JM. J Surg Oncol. 2015 Nov;112(6):597-602. doi: 10.1002/jso.24050. Epub 2015 Sep 23.
  • Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer. Almhanna K, Hoffe S, Strosberg J, Dinwoodie W, Meredith K, Shridhar R. J Gastrointest Oncol. 2015 Feb;6(1):39-44. doi: 10.3978/j.issn.2078-6891.2014.101.
  •  Robotic assisted Ivor Lewis esophagectomy in the elderly patient.  Abbott A, Shridhar R, Hoffe S, Almhanna K, Doepker M, Saeed N, Meredith K. J Gastrointest Oncol. 2015 Feb;6(1):31-8. doi: 10.3978/j.issn.2078-6891.2014.095.
  • Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer. Baksh K, Prithviraj G, Kim Y, Hoffe S, Shridhar R, Coppola D, Centeno B, Pimiento J, Meredith K, Almhanna K. Am J Clin Oncol. 2015 Dec 22. [Epub ahead of print]
Back to Top

2014

  • Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 Dec 4; 371(23):2167-77. doi: 10.1056/NEJMoa1408440. 
  • Wakelee H, Zvirbule Z, Braud F, Kingsley D, Mekhail T, Schütte W,.Lena H, Lawler W, Braiteh F, Cosgriff T, Kaen D, Boyer M, Hsu J, Phan S, Novello S. Efficacy and safety of onartuzumab in combination with first-line bevacizumab- or pemetrexed-based chemotherapy regimens in advanced non-squamous non-small-cell lung cancer (nsNSCLC): results from a phase II, placebo-controlled study (GO27821).  2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
  • Nakagawa L, Mok T, Kim D, Wu Y, Solomon B, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tursi J, Blackhall F. First-line crizotinib vs. pemetrexed + cisplatin/carboplatin in Asian patients with advanced ALK+ NSCLC in PROFILE 1014.   12th Annual Meeting JSMO, July 2014.  
  • .Mok T, Kim D, Wu Y, Solomon B, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tursi J, Blackhall F. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)  J Clin Oncol 32:5s, 2014 (suppl; abstr 8002). 
  • Sharma N, Pennell N, Nickolich M, Halmos B, Ma P, Mekhail T, Fu P, Dowlati A. Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Invest New Drugs. 2014 Apr; 32(2):362-8. Epub 2014 Jan 15.
  • Blackhall  FH, Felip E, Cappuzzo F, Kim DW, Wu Y, Solomon B, Nakagawa K, Mekhail T, Paolini J, Usare T, Iyer S, Reisman A, Wilner K, Tursi J, Mok TS. Impact of Crizotinib on Patient-reported Symptoms and Global QOL Compared with Platinum-Based Chemotherapy in a Phase III Study of Treatment-Naïve Advanced ALK-positive NSCLC. ESMO 2014, Poster Discussion.
  • Soria J, Sequist LV, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Yu HA, Solomon BJ, Ou SH, Papadimitrakopoulou V, Oxnard GR, Horn L, Dziadziuszko R, Chao B, Spira AI, Liu S, Mekhail T, Matheny S, Litten J, Camidge RD. Title: Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer.  Plenary Session, 2014 EORTC-NCI-AACR, Barcelona, Spain.
  • Almhanna K, Hoffe S, Strosberg J, Dinwoodie W, Meredith K, Shridhar R.    Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally         advanced resectable esophageal cancer. J Gastrointest Oncol. 2015 Feb;6(1):39-44. doi: 10.3978/j.issn.2078-       6891.2014.101. PMID: 25642336 [PubMed]
  • Abbott A, Shridhar R, Hoffe S, Almhanna K, Doepker M, Saeed N, Meredith K. Robotic assisted Ivor Lewis esophagectomy in the elderly patient. J Gastrointest Oncol. 2015 Feb;6(1):31-8. doi: 10.3978/j.issn.2078- 6891.2014.095.  PMID:25642335[PubMed]
  • Ahmed KA, Correa CR, Dilling TJ, Rao NG, Shridhar R, Trotti AM, Wilder RB, Caudell JJ.  Altered fractionation schedules in radiation treatment: a review. Semin Oncol. 2014 Dec;41(6):730-50. doi: 10.1053/j.seminoncol.2014.09.012. Epub 2014 Oct 6. Review.PMID:25499633 [PubMed - indexed for MEDLINE]
  • Shridhar R, Freilich J, Hoffe SE, Almhanna K, Fulp WJ, Yue B, Karl RC, Meredith K. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus. Ann Surg Oncol. 2014 Nov;21(12):3744-50. doi: 10.1245/s10434-014-3795-2. Epub 2014 May 23. PMID:24854492[PubMed - in process]
Back to Top

2013

  • Mekhail T, Waterhouse, D. M., Hadley, T. J., Webb, C. D., Burris, H.A., Hainsworth, J. D., Greco, A. , Spigel, D. R. First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type (WT) non-small cell lung cancer (NSCLC).  Journal of Clinical Oncology 31, 2013 (supplement)
  • Halmos B., Penell, N., Otterson G., Gadgeel, S. , Mekhail, T.,  et al. Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotnib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses.   Journal of Clinical Oncology 31, 2013 (supplement).
  • Jones, C. V., Du, L., Elson, P., Mekhail, T., Pennel, N. , Sadraie, N.  Predictors of outcome for pemetrexed (PEM) in metastatic NSCLC (mNSCLC).  Journal of Clinical Oncology 31, 2013 (supplement).
  •  Fakhreijahani, F., Hashemi Sadraei, N., Mekhail T.  The role of consolidation treatment in locally advanced unresectable NSCLC.  Current Oncology Report, 2013, Aug: 15(4):424-32.
  • Mekhail T, Waterhouse, D. M., Hadley, T. J., Webb, C. D., Burris, H.A., Hainsworth, J. D., Greco, A. , Spigel, D. R.  First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type (WT) non-small cell lung cancer (NSCLC).  2013 ASCO Annual Meeting.
  • Halmos B., Penell, N., Otterson G., Gadgeel, S. , Mekhail, T.,  et al. Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotnib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses. 2013 ASCO Annual Meeting.
Back to Top

2012

  • Mikhail M, Mekhail Y, Mekhail T. Thymic neoplasms: a clinical update. Curr Oncol Rep. 2012 Aug;14(4):350-8. Review. 
  • Schwandt A, Mekhail T, Halmos B, O'Brien T, Ma PC, Fu P, Ivy P, Dowlati A. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer.  J Thorac Oncol. 2012 Apr;7(4):751-4.
  • Mazzone P, Mekhail T. Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists.  Respir Med. 2012 Apr;106(4):473-92.. Epub 2011 Nov 25. Review.
  • Mazzone PJ, Wang XF, Xu Y, Mekhail T, Beukemann MC, Na J, Kemling JW, Suslick KS, Sasidhar M. Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer.  J Thorac Oncol. 2012 Jan;7(1):137-42..     
  • Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res. 2011 Dec 15;17(24):7754-64.
  • Garcia JA, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.  BJU Int. 2012 Jan;109(1):63-9.. Epub 2011 Jan 18.
  • Santos ES, Mekhail T. A strong step forward in maintenance therapy for non-small cell lung cancer treatment. Transl Lung Cancer Res 2012;1(2):99-101.
  • Santos ES, Mekhail T. A strong step forward in maintenance therapy for non-small cell lung cancer treatment. Transl Lung Cancer Res 2012;1(2):99-101.
  • Amrubicin and carboplatin with pegfilgrastim in patients with extensive-stage small-cell lung cancer (ES-SCLC): A phase II study of the Sarah Cannon Research Institute (SCRI).  Abstract  2012 ASCO Annual Meeting, Chicago, IL
  • Interim safety analysis of anti-EGFL7 (MEGF0444A) in combination with bevacizumab (bev), carboplatin and paclitaxel in patients with previously untreated advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Abstract  2012 ASCO Annual Meeting, Chicago, IL
Back to Top

2011

Back to Top

2010

  • Murthy SC, Reznik SI, Ogwudu UC, Farver CF, Arrossi A, Batizy LH, Nowicki ER, Mekhail TM, Mason DP, Rice TW, Blackstone EH.  Winning the battle, losing the war: the noncurative “curative” resection for stage I adenocarcinoma of  the lung. Ann Thorac Surg. 2010 Oct;90(4):1067-74.
  • Garcia JA, Mekhail T, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI.  Clinical and immunomodulatory effects of bevacizumab and low-does interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int. 2011 Feb;107(4):562-70. doi: 10.1111/j.1464-410X.2010.09573.x. Epub 2010 Sep 14 .
  • Luszczek W, Cheriyath V, Mekhail TM, Borden EC. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther. 2010 Aug;9(8):2309-21. Epub 2010 Aug 3.
  • Mekhail T, Masson E, Fischer BS, Gong J, Iyer R, Gan J, Pursley J, Patricia D, Williams D, Ganapathi R. Metabolism, excretion, and pharmocokinetcis of oral brivanib in patients with advance or metastatic solid tumors. Drug Metab Dispos. 2010 Nov;38(11):1962-6. Epub 2010 Jul 29.
  • Mekhail T, Boyer J.  Limited resection for early-stage lung cancer. Curr Oncol Rep. 2010 Sep;12(5):285-7. 
Back to Top

2009

  • Small vessel ischemic disease of the brain and brain metastases in lung cancer patients.  Mazzone PJ, Marchi N, Fazio V, Taylor JM, Masaryk T, Bury L, Mekhail T, Janigro D. PLoS One. 2009 Sep 30;4(9):e7242.
  • A phase I study of sunitinib plus bevacizumab in advanced solid tumors.  Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. Clin Cancer Res. 2009 Oct 1;15(19):6277-83. Epub 2009 Sep 22.
  • A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience.  Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Mason D, Murthy S, Rice TW, Mazzone P, Machuzak M, Mekhail T, Videtic GM. J Thorac Oncol. 2009 Aug;4(8):976-82.
  • Investigational agents in the management of non-small cell lung cancer. Pennell NA, Mekhail T. Curr Oncol Rep. 2009 Jul;11(4):275-84.  Review.
  • Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification. Videtic GM, Reddy CA, Chao ST, Rice TW, Adelstein DJ, Barnett GH, Mekhail TM, Vogelbaum MA, Suh JH. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1141-7. Epub 2009 Mar 26.
Back to Top